Richard Cappetta, President and CEO of MicroVention, Inc., said: "The HEAT trial is intended to provide evidence that our second-generation hydrogel coil technologies provide superior long-term ...
HOUSTON -- Treating medium-sized intracranial aneurysms with second-generation hydrogel coils diminished adverse outcomes compared with standard platinum coils, researchers reported here. Physicians ...
May 20, 2011 — For endovascular treatment of intracranial aneurysms, hydrogel-coated coils are safe, with no evidence of worse clinical outcomes compared with bare platinum coils, and are associated ...
MIAMI & ALISO VIEJO, Calif.--(BUSINESS WIRE)-- MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, is celebrating a decade of legacy innovation ...
Please provide your email address to receive an email when new articles are posted on . Patients with intracranial aneurysms who underwent embolization with second-generation hydrogel-coated coils ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced that the SOFIA™ EX 5F 115 cm Intracranial ...
US-based neuroendovascular device company MicroVention has announced a court settlement against three former members of staff accused of misappropriating trade secrets about the company’s embolic ...
DUBLIN, Oct. 19, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/j87v3m/global) has announced the addition of the "Global ...
Research and Markets has announced the addition of the "Global Neuroendovascular Coil and Non-Coil Devices Market - Growth, Trends and Forecasts (2016 - 2021)" report to their offering. The research ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results